Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Multiple Sclerosis and Demyelinating Disease: Clinical Treatment and Management
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Multiple Sclerosis and Demyelinating Disease: Clinical Treatment and Management

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".

Deadline for manuscript submissions: 25 May 2026 | Viewed by 1912

Special Issue Editor

Prof. Dr. Sotirios Giannopoulos

E-Mail Website
Guest Editor
Second Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece
Interests: neurological diseases; multiple sclerosis; stroke; ischemic stroke
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Special Issue “Multiple Sclerosis and Demyelinating Disease: Clinical Treatment and Management” invites submissions that explore advances in the diagnosis, treatment, and long-term care of multiple sclerosis (MS) and related demyelinating disorders. Despite significant progress in immunology, neuroimaging, and therapeutic development, these conditions continue to present substantial clinical challenges. We welcome high-quality original research articles, reviews, and meta-analyses focusing on disease-modifying therapies, emerging immunological and neuroprotective strategies, symptom management, rehabilitation, cognitive and psychological support, and multidisciplinary care models. Equally important are studies exploring the use of biomarkers, imaging, and digital health tools to improve diagnosis, prognosis, and monitoring. This Special Issue aims to foster critical discussion and disseminate evidence that will inform future therapeutic strategies and improve patient outcomes in multiple sclerosis and demyelinating disease.

Prof. Dr. Sotirios Giannopoulos
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multiple sclerosis
  • demyelinating disease
  • comorbidities
  • disease modifying treatments
  • neuromuscular disorder
  • myasthenia gravis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

17 pages, 1608 KB  
Article
Characteristics of Disease Relapses and Their Relationships with Weather Conditions in Patients with Multiple Sclerosis
by Izabela Sempik, Anna Pokryszko-Dragan, Małgorzata Wieczorek, Marek Błaś and Edyta Dziadkowiak
J. Clin. Med. 2025, 14(22), 7960; https://doi.org/10.3390/jcm14227960 - 10 Nov 2025
Viewed by 1090
Abstract
Background: The aim of the study was to analyze the clinical characteristics and circumstances of relapses in the patients with relapsing-remitting multiple sclerosis (MS). Objectives: The eighty patients with clinically definite MS and relapsing-remitting course were enrolled in the retrospective study. [...] Read more.
Background: The aim of the study was to analyze the clinical characteristics and circumstances of relapses in the patients with relapsing-remitting multiple sclerosis (MS). Objectives: The eighty patients with clinically definite MS and relapsing-remitting course were enrolled in the retrospective study. Methods: The calendar of documented recurrences was analyzed, looking for any patterns across years, warm and cold periods, and seasons and months. Results: In the years 2015–2020 the majority of relapses occurred in March, June–July, and October; with regard to seasons, the relapse rate peaked during spring and summer. In 2021–2023 there was significant increase in relapses in May and in February. In these years, most cases occurred in spring, and the least in autumn. The most significant coincidences were found for sensory symptoms in January, optic neuritis in March, motor deficit with pyramidal signs in May and June, cerebellar symptoms in March and July, and spinal cord involvement signs in August. Conclusions: Observation of seasonal occurrence of relapses revealed periods with high temperature, low humidity, and variable atmospheric pressure as potential contributors. Better recognition of these issues within future investigations could be considered in the complex approach to the management of MS outcomes. Full article
(This article belongs to the Special Issue Multiple Sclerosis and Demyelinating Disease: Clinical Treatment and Management)
►▼ Show Figures

Graphical abstract

Other

Jump to: Research

12 pages, 1326 KB  
Systematic Review
Neuropathic Pain in Neuromyelitis Optica Spectrum Disorders: Prevalence and Management Strategies—A Systematic Review and Meta-Analysis
by Alexandra Akrivaki, Vasileios Giannopapas, Evangelia-Makrina Dimitriadou, Dimitrios Tzanetakos, Dimitrios Kitsos, Konstantina Stavrogianni, Athanasios K. Chasiotis, Georgios Tsivgoulis, John S. Tzartos and Sotirios Giannopoulos
J. Clin. Med. 2026, 15(4), 1378; https://doi.org/10.3390/jcm15041378 - 10 Feb 2026
Viewed by 576
Abstract
Introduction: Neuropathic pain (NP) in neuromyelitis optica spectrum disorder (NMOSD) represents a significant and often under-recognized complication arising from central nervous system (CNS) lesions. Unlike other demyelinating disorders, NMOSD involves a distinct immunopathogenesis primarily driven by aquaporin-4 antibodies (AQP4-IgG), leading to severe inflammatory [...] Read more.
Introduction: Neuropathic pain (NP) in neuromyelitis optica spectrum disorder (NMOSD) represents a significant and often under-recognized complication arising from central nervous system (CNS) lesions. Unlike other demyelinating disorders, NMOSD involves a distinct immunopathogenesis primarily driven by aquaporin-4 antibodies (AQP4-IgG), leading to severe inflammatory damage. NP is typically the consequence of inflammatory damage to the spinothalamic tract or dorsal columns, resulting in both acute and chronic pain syndromes. Methods: A systematic review and meta-analysis were conducted following a comprehensive search of Medline and Scopus, identifying nine eligible studies reporting on NP in NMOSD. Results: Pooled prevalence was estimated using a random-effects metaprop meta-analysis with Freeman–Tukey transformation and REML-based heterogeneity estimation. The pooled prevalence of NP among patients with NMOSD was 56.2% (95% CI: 41.7–70.1%; I2 = 95.3%, p < 0.001). Sensitivity analysis including only AQP4-IgG+ cohorts revealed a prevalence of 63.2% (95% CI: 23.4–94.7%; I2 = 98.1%, p < 0.001). No significant difference was found between mixed and AQP4-IgG+-only populations (53.05% vs. 63.27%, p = 0.63). Meta-regression showed no significant associations between NP prevalence and age (β = 0.01, p = 0.33) or disability (β = 0.08, p = 0.18). Qualitative synthesis demonstrated an association between thoracic spinal cord lesions and NP, and also indicated that NP was often resistant and refractory to standard pharmacologic therapies. Conclusions: NP affects one in two NMOSD patients, and is associated with thoracic spinal cord lesions. In comparison with multiple sclerosis, NP in NMOSD is primarily structural and immunopathological in origin. Treatment strategies remain inadequate, emphasizing the need for early recognition and a disease-specific therapeutic approach. Full article
(This article belongs to the Special Issue Multiple Sclerosis and Demyelinating Disease: Clinical Treatment and Management)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop